COMMUNIQUÉS West-GlobeNewswire

Fangzhou Releases 2026 Interim Report, Deepening "AI + Chronic Care" as a Lifetime Health Service Partner
25/09/2026
SHANGHAI, China, Sept. 25, 2026 (GLOBE NEWSWIRE) -- Fangzhou Inc. (“Fangzhou” or the “Company”) (HKEX: 06086), a leading provider of AI‑driven Internet healthcare solutions, has released its 2026 interim report, [...]
Integra LifeSciences Marks 20 Years of CUSA® Technology with Liver Surgery Education at ACS Clinical Congress 2026
25/09/2026
Company to feature surgeon-led educational programming and technologies supporting liver surgery PRINCETON, N.J., Sept. 25, 2026 (GLOBE NEWSWIRE) -- Integra LifeSciences (Nasdaq: IART) will mark 20 years of CUSA® [...]
Kraig Labs’ Atlas Milestone Opens the Door to Potential Historic Spider Silk Advancements
25/09/2026
DENVER, Sept. 25, 2026 (GLOBE NEWSWIRE) -- ( 247marketnews.com ) -- A completed library of living genetic building blocks positions Kraig Biocraft Laboratories (OTCQB: KBLB) to explore more than 200 potential [...]
SBC Medical to Participate in Several Upcoming Investor Conferences in October 2026
25/09/2026
IRVINE, Calif., Sept. 25, 2026 (GLOBE NEWSWIRE) -- SBC Medical Group Holdings Incorporated (Nasdaq: SBC) (“The Company” or “SBC Medical”), a Medical Services Organization (MSO) providing management support across a wide [...]
Tilray Brands to Announce First Quarter Fiscal Year 2027 Financial Results on October 8, 2026
25/09/2026
NEW YORK and LONDON and LEAMINGTON, Ontario, Sept. 25, 2026 (GLOBE NEWSWIRE) -- Tilray Brands, Inc . (“Tilray” or the “Company”) (Nasdaq: TLRY; TSX: TLRY), a global lifestyle and consumer packaged goods company at the [...]
INVO Fertility to Participate in the Lytham Partners Fall 2026 Investor Conference
25/09/2026
SARASOTA, Fla., Sept. 25, 2026 (GLOBE NEWSWIRE) -- INVO Fertility, Inc. (Nasdaq: IVF) ("INVO Fertility" or the "Company"), a healthcare fertility company focused on the establishment, acquisition, and operation of [...]
Knowtex, the First Frontier AI Lab for Healthcare, Named Prime Awardee on VA's Nine-Figure Ambient Scribe Enterprise Contract
25/09/2026
One of two prime awardees on the $775.72 million multiple-award IDIQ, Knowtex is expanding AI that gives clinicians more time with Veterans. It's already live at 79 VA medical centers and more than 310 VA facilities [...]
Teladoc Health Announces Chief Legal Officer Transition
25/09/2026
Jonathan Dorfman to be promoted to Chief Legal Officer and Secretary effective November 2, 2026 NEW YORK, Sept. 25, 2026 (GLOBE NEWSWIRE) -- Teladoc Health, Inc. (NYSE: TDOC), the global leader in virtual care, today [...]
CDT Equity Inc. Announces Reverse Stock Split
25/09/2026
NAPLES, Fla. and CAMBRIDGE, United Kingdom, Sept. 25, 2026 (GLOBE NEWSWIRE) -- CDT Equity Inc. (Nasdaq: CDT) (“CDT” or the “Company”), announces that its board of directors has approved a 1-for-25 reverse stock split of [...]
Adaptive Biotechnologies Highlights Role of Highly Sensitive MRD Testing in New International Myeloma Society Definition of Cure
25/09/2026
Definition requires five years off myeloma treatment with sustained MRD negativity, assessed with technology sensitive enough to identify one myeloma cell among one million cells SEATTLE, Sept. 25, 2026 (GLOBE NEWSWIRE [...]
neurocare and Wave Neuroscience partner to expand patient access to FDA-Cleared MeRT® therapy for PTSD on the Apollo TMS Therapy System
25/09/2026
Munich, Germany and Alpharetta, GA, United States, September 25, 2026 - neurocare group AG (“neurocare” or the “Company”), a best practice platform for mental health and performance, and the company behind the neurocare [...]
Firefly (NASDAQ: AIFF) and NeuroSigma Partner to Expand Access to First FDA-Cleared, Non-Drug Treatment for Pediatric ADHD
25/09/2026
– Partnership will introduce NeuroSigma’s second-generation Monarch eTNS ® System to Firefly’s nationwide network of Evoke™ clinicians – – Collaboration brings together an FDA-cleared pediatric ADHD treatment and [...]
Cerenome to Hold CNSide® Business Update Call on September 30, 2026
25/09/2026
Management to provide updates on recent developments including diagnostic billing, market access & growth plans HOUSTON, Sept. 25, 2026 (GLOBE NEWSWIRE) -- CNSide Diagnostics, LLC, a wholly-owned subsidiary of [...]
Single infusion of CARVYKTI®▼ (ciltacabtagene autoleucel) delivered five-year treatment-free remissions in 50% of patients in early line relapsed/refractory multiple myeloma
25/09/2026
New results from cohort A of the CARTITUDE-2 study, among 20 patients, suggest earlier treatment may increase the likelihood of long-term remission 1 Study adds to Johnson & Johnson's overwhelming body of evidence [...]
Ocugen Receives Provisional Approval and Priority Designation Under the Longevity and Regenerative Therapies Act in The Bahamas to Provide OCU400 to Patients for Treatment of Retinitis Pigmentosa
25/09/2026
Ocugen will provide its investigational modifier gene therapy OCU400 through an expanded access program (EAP), with the goal of enabling the first patient to be treated for retinitis pigmentosa (RP) within 90 days, [...]
Legend Biotech Presents CARVYKTI Data Showing Half of Patients with RRMM Remained Progression-Free and Alive Five Years After a Single Infusion
25/09/2026
Five-year overall survival rate was 69.2%, adding to growing long-term evidence supporting the curative potential of CARVYKTI in earlier-line RRMM BRIDGEWATER, N.J., Sept. 25, 2026 (GLOBE NEWSWIRE) -- Legend Biotech [...]
C4 Therapeutics Presents New Biomarker Data from the Cemsidomide Phase 1 Trial with Dexamethasone and Phase 1b Trial with Elranatamab (ELREXFIO®) in Relapsed/Refractory Multiple Myeloma at the 23rd International Myeloma Society (IMS) Annual Meeting
25/09/2026
Immunomodulatory Effects of Cemsidomide with Dexamethasone from Phase 1 Trial Demonstrated Robust T-cell Activation, a Key Component of Cemsidomide’s Dual Mechanism of Action Biomarker Data from First Two Patients in [...]
Fate Therapeutics Announces Receipt of California Institute for Regenerative Medicine (CIRM) CLIN2 Grant to Advance RECLAIM-LN
25/09/2026
$15.0 Million Award to Support Advancement of RECLAIM-LN, a Phase 2 Potentially Registrational Trial of FT819 Off-the-Shelf CAR T-Cell Therapy in Lupus Nephritis CLIN2 Grant is a highly competitive award from CIRM to [...]
Sernova Biotherapeutics to Participate in Noble Capital Markets’ Emerging Growth Virtual Equity Conference
25/09/2026
Jonathan Rigby and Will Rust, Ph.D., to Discuss Proposed Merger to Form BetaNova Biotherapeutics and Advance a Differentiated Type 1 Diabetes Cell-Replacement Platform TORONTO and GERMANTOWN, Md., Sept. 25, 2026 (GLOBE [...]

Pages

Other news

Promaxo Announces Closing of Series C Financing and $100M Credit Facility

Contenu:

The growth capital will expand manufacturing capacity, reduce backlog, and support new regulatory filings

ProKidney to Host Virtual KOL Event to Recap Mechanism of Action Data Presented at ASN Kidney Week and Provide a Corporate Update

Contenu:

WINSTON-SALEM, N.C., Oct. 22, 2026 (GLOBE NEWSWIRE) -- ProKidney Corp.

BreathiZen Introduces BreathiZen Spray - A New Multi-Ingredient Dietary Supplement For Your Respiratory Wellness

Contenu:

BreathiZen is a once-daily oral spray that brings together botanical extracts, an enzyme preparation, and selected nutrients in a 60 ml bottle designed to fit easily into an adult wellness routine.

New York, Oct. 22, 2026 (GLOBE NEWSWIRE) --

RenovoRx to Report Third Quarter 2026 Financial Results and Business Highlights on November 5, 2026

Contenu:

Company to host conference call on November 5, 2026, at 4:30 p.m. ET

BridgeBio to Report Third Quarter 2026 Financial Results and Commercial Updates on October 29, 2026 at 4:30 pm ET

Contenu:

PALO ALTO, Calif., Oct. 22, 2026 (GLOBE NEWSWIRE) -- BridgeBio Pharma, Inc.

Ernexa Therapeutics Highlights ERNA-101’s Path Toward the Clinic and Differentiated Cell Therapy Platform in New “What This Means” Segment

Contenu:

Leadership discusses recent FDA engagement, the technology underlying ERNA-101 and the development strategy supporting planned first-in-human clinical evaluation

SciSparc: Subsidiary NeuroThera Labs Reports Positive Progress in FDA-Approved Phase IIb Clinical Trial for Tourette Syndrome

Contenu:

TEL AVIV, Israel, Oct. 22, 2026 (GLOBE NEWSWIRE) -- SciSparc Ltd. (Nasdaq: SPRC) (“Company” or “SciSparc”), today announced that its subsidiary, NeuroThera Labs Inc.